{"id":2206,"date":"2021-05-19T09:12:57","date_gmt":"2021-05-19T08:12:57","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&p=2206"},"modified":"2023-03-07T11:52:06","modified_gmt":"2023-03-07T11:52:06","slug":"andrew-blauvelt-aad-vmx-2021-abrocitinib-jade-regimen-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/atopic-dermatitis\/conference-hub\/andrew-blauvelt-aad-vmx-2021-abrocitinib-jade-regimen-trial\/","title":{"rendered":"Andrew Blauvelt, Dermatology Meeting News 2021: Abrocitinib JADE REGIMEN Trial"},"content":{"rendered":"

It was a pleasure to speak with Dr Andrew Blauvelt<\/strong> (Oregon Medical Research Center, Portland, OR, USA) about the results from the JADE REGIMEN Phase 3 trial (NCT03627767) investigating abrocitinib in patients with atopic dermatitis.<\/p>\n

The abstract entitled \u2018Abrocitinib Induction, Randomized Withdrawal and Response Recapture With Rescue Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE REGIMEN Phase 3 Trial<\/em>\u2019 was presented at AAD VMX, 23-25 April 2021.<\/p>\n

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.\u00a0\u00a0<\/em><\/p>\n

Questions<\/strong><\/p>\n

    \n
  1. What is the rationale for the use of abrocitinib in the treatment of adults with moderate to severe atopic dermatitis? (0:14)<\/span><\/li>\n
  2. Could you tell us about the unique design of the JADE REGIMEN Phase 3 study? (0:55)<\/span><\/li>\n
  3. What was the response to abrocitinib in the induction, maintenance and rescue periods? (3:09)<\/span><\/li>\n
  4. What was the safety profile of abrocitinib, and how can adverse events be minimized? (4:52)<\/span><\/li>\n
  5. What are the significance of these findings in terms of the evolving treatment paradigm for atopic dermatitis? (6:18)<\/span><\/li>\n<\/ol>\n

    Disclosures<\/strong>: Dr. Andrew Blauvelt has served as a scientific adviser and\/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.<\/span><\/p>\n

    Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.<\/p>\n

    Filmed in coverage of the AAD VMX 2021.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    It was a pleasure to speak with Dr Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the JADE REGIMEN Phase 3 trial (NCT03627767) investigating abrocitinib in patients with atopic dermatitis. The abstract entitled \u2018Abrocitinib Induction, Randomized Withdrawal and Response Recapture With Rescue Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: Results […]<\/p>\n","protected":false},"featured_media":2207,"template":"","class_list":["post-2206","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-atopic-dermatitis"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":6,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2206\/revisions"}],"predecessor-version":[{"id":11457,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2206\/revisions\/11457"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/2207"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=2206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}